Aarti Drugs: GST Dept Challenges Bombay HC Order, Files SLP in Supreme Court
Aarti Drugs' GST litigation continues as the GST Department files a Special Leave Petition in the Supreme Court challenging the Bombay High Court's order. The dispute involves a potential demand of ₹230.70 Crores related to IGST refunds, interest, and penalties. The company is defending its position, and the financial impact is currently unclear.
The litigation involves a significant potential demand of ₹230.70 Crores, which, if materialized, could impact the company's financials. Although the final outcome is uncertain and currently difficult to assess, the scale of the claim warrants a medium impact assessment.
The company is updating on a legal challenge filed by the GST department against a favorable High Court order. While the company intends to defend its position, the sub-judice nature of the matter and the potential financial implications introduce uncertainty, balancing out any immediate positive or negative sentiment.
Aarti Drugs Limited has informed the stock exchanges about a new development in a Goods and Services Tax (GST) related litigation. The company had previously received an intimation regarding an order passed by the Hon’ble High Court at Judicature at Bombay, which allowed a Writ Petition and set aside an order issued by the CGST & C.Ex. Authority. This earlier order had dropped a demand of ₹209.98 Crores related to alleged contravention of Rule 96(10) of CGST Rule, while including a demand of erroneous sanctioned IGST refund of ₹20.72 Crores along with applicable interest and penalty.
However, the GST Department has now challenged the High Court's order by filing a Special Leave Petition (SLP) before the Hon’ble Supreme Court of India. The dispute initially stemmed from a Show Cause Notice for alleged contravention of Rule 96(10) of CGST Rule, proposing a demand of IGST amounting to ₹230.70 Crores, plus interest and penalty, for the financial years 2017-18 to 2021-22.
The company stated that it is difficult to assess the financial impact at this stage, as the matter is sub-judice before the Hon’ble Supreme Court. Aarti Drugs Limited intends to take appropriate legal steps to defend its position and will update the stock exchanges on any material developments.
What to do with a filing like this
Aarti Drugs Limited filed this with the NSE as a statutory disclosure, categorised under litigation updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Drugs Limited. Read the original for the full detail.